Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PELP1-siRNA liposomes
- Development stage
- Preclinical
- Lead developer
- Nagoya City University
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intraperitoneal, Intravenous
01
Overview
PELP1-siRNA liposomes (also known as PELP1-siRNA-DOPC) is a research-stage nanoliposomal RNA interference (RNAi) therapeutic. The active ingredient is a small interfering RNA (siRNA) targeting proline-, glutamic acid-, and leucine-rich protein 1 (PELP1), an oncogenic estrogen receptor coregulator and scaffolding protein. The siRNA is encapsulated in neutral 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC) nanoliposomes, which enable systemic delivery and tumor penetration. By silencing PELP1 expression, the therapeutic inhibits both genomic and non-genomic estrogen receptor signaling, thereby suppressing tumor growth, metastasis, and resistance to endocrine therapies. It has been investigated preclinically for the treatment of ovarian cancer, breast cancer, and hepatocellular carcinoma.
- Other names
- PELP1-siRNA-DOPCPELP-1-siRNA-DOPCPELP 1-siRNA-DOPCliposomal PELP1-siRNA-DOPC
02
Targets
Proline-, glutamic acid- and leucine-rich protein 1 (PELP1) mRNA
Beyond the preview
Go deeper on PELP1-siRNA liposomes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PELP1-siRNA liposomes.